Semaglutide Slowed a Blood-Based Dementia Risk Score in Older Heart Patients
- Design
- —
- Participants
- 2,970
- Duration
- —
- Funding
- Two authors work for and own shares in Novo Nordisk, which makes semaglutide…
This analysis suggests GLP-1 drugs may affect brain-related blood markers, though actual dementia outcomes remain untested.
Older adults with excess weight and heart disease but no diabetes took semaglutide or a placebo for two years. A 25-protein blood test that predicts future dementia risk rose much less in the semaglutide group. This isn't proof of fewer dementia cases, just a slower rise in a risk marker. Still, it adds to the idea that GLP-1 drugs may do something for the aging brain.
Conflict of Interest Disclosure: Two authors work for and own shares in Novo Nordisk, which makes semaglutide; another author consults for Novo Nordisk.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Related Studies
All researchThe Rare APOE2 Gene Protects the Brain by Keeping Blood Vessel Cells Clean
Most people know APOE4 as the gene that raises Alzheimer's risk.
Ozempic-Style Drugs May Slow Biological Aging, Not Just Shrink Waistlines
GLP-1 drugs like semaglutide cut deaths and heart problems by more than their weight and blood sugar effects alone would explain.
Why Muscle Quality Matters So Much on GLP-1 Weight Loss Drugs
Drugs like Ozempic drop weight fast, but some of that loss is muscle, not just fat.